Icure Pharm Overview
- Year Founded
-
2000

- Status
-
Public
- Employees
-
293

- Stock Symbol
-
175250

- Investments
-
2
- Share Price
-
$1.17
- (As of Friday Closing)
Icure Pharm General Information
Description
Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.
Contact Information
Website
www.icure.co.krCorporate Office
- 10 Bongeunsa-Ro 104-Gil, Gangnam-Gu
- Seoul, Seocho-gu 06170
- South Korea
Corporate Office
- 10 Bongeunsa-Ro 104-Gil, Gangnam-Gu
- Seoul, Seocho-gu 06170
- South Korea
Icure Pharm Stock Performance
As of 14-Feb-2025, Icure Pharm’s stock price is $1.17. Its current market cap is $43.8M with 37.4M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.17 | $1.13 | $1.12 - $2.51 | $43.8M | 37.4M | 252K | $0.01 |
Icure Pharm Financials Summary
As of 30-Sep-2024, Icure Pharm has a trailing 12-month revenue of $45M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 69,574 | 108,272 | 119,398 | 331,130 |
Revenue | 45,046 | 43,448 | 45,946 | 56,122 |
EBITDA | 10,342 | (14,209) | (22,370) | (23,211) |
Net Income | 387 | (24,032) | (32,324) | (33,321) |
Total Assets | 108,046 | 128,921 | 177,464 | 181,046 |
Total Debt | 28,772 | 59,292 | 67,220 | 60,911 |
Icure Pharm Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Icure Pharm Patents
Icure Pharm Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2020158514-A | Cataplasm agent containing ultraviolet-curable hydrogel for transdermal administration | Active | 11-Feb-2016 | ||
US-20190046463-A1 | Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same | Active | 11-Feb-2016 | ||
EP-3415141-A1 | Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same | Pending | 11-Feb-2016 | ||
US-11382868-B2 | Transdermal uv-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same | Active | 11-Feb-2016 | ||
EP-3415141-A4 | Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same | Pending | 11-Feb-2016 | A61K9/703 |
Icure Pharm Signals
Icure Pharm Investments & Acquisitions (2)
Icure Pharm’s most recent deal was a Merger/Acquisition with Bio Rosette for . The deal was made on 23-Dec-2019.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Bio Rosette | 23-Dec-2019 | Merger/Acquisition | Other Commercial Products | ||
Cosmax ICure | 01-Dec-2014 | Joint Venture | Distributors/Wholesale |
Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
Bio Rosette | Seoul, South Korea | 1986 |
Icure Pharm FAQs
-
When was Icure Pharm founded?
Icure Pharm was founded in 2000.
-
Where is Icure Pharm headquartered?
Icure Pharm is headquartered in Seoul, South Korea.
-
What is the size of Icure Pharm?
Icure Pharm has 293 total employees.
-
What industry is Icure Pharm in?
Icure Pharm’s primary industry is Drug Discovery.
-
Is Icure Pharm a private or public company?
Icure Pharm is a Public company.
-
What is Icure Pharm’s stock symbol?
The ticker symbol for Icure Pharm is 175250.
-
What is the current stock price of Icure Pharm?
As of 14-Feb-2025 the stock price of Icure Pharm is $1.17.
-
What is the current market cap of Icure Pharm?
The current market capitalization of Icure Pharm is $43.8M.
-
What is Icure Pharm’s current revenue?
The trailing twelve month revenue for Icure Pharm is $45M.
-
What is Icure Pharm’s annual earnings per share (EPS)?
Icure Pharm’s EPS for 12 months was $0.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »